CONMED Corporation Reports Q2 2025 Sales Increase of 3.1%; Adjusted EPS Rises to $1.15

Reuters

07/31

<a href="https://laohu8.com/S/CNMD">CONMED Corporation</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Sales Increase of 3.1%; Adjusted EPS Rises to $1.15

CONMED Corporation (NYSE: CNMD) announced its financial results for the second quarter ended June 30, 2025. The company reported sales of $342.3 million, marking a 3.1% increase year-over-year as reported, and a 2.9% increase in constant currency. Domestic revenue rose by 2.8% compared to the previous year, while international revenue saw a 3.4% increase year-over-year as reported, and a 2.9% rise in constant currency. The company reported diluted net earnings per share (GAAP) of $0.69, a decrease from $0.96 in the second quarter of 2024. However, adjusted diluted net earnings per share were $1.15, up from $0.98 in the second quarter of 2024. Looking ahead, CONMED has updated its full-year revenue guidance, now expecting reported revenue to be between $1.356 billion and $1.378 billion, an adjustment from the prior range of $1.350 billion to $1.378 billion. The company noted that currency headwinds are now expected to be immaterial, compared to the previously anticipated 50 to 70 basis points of headwind.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CONMED Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730169915) on July 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555840024"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555840024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555840024?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555840024","market":"nz","top_or_hot":-1,"title":"CONMED Corporation Reports Q2 2025 Sales Increase of 3.1%; Adjusted EPS Rises to $1.15","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNMD\">CONMED Corporation</a> Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Sales Increase of 3.1%; Adjusted EPS Rises to $1.15\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CONMED Corporation (NYSE: CNMD) announced its financial results for the second quarter ended June 30, 2025. The company reported sales of $342.3 million, marking a 3.1% increase year-over-year as reported, and a 2.9% increase in constant currency. Domestic revenue rose by 2.8% compared to the previous year, while international revenue saw a 3.4% increase year-over-year as reported, and a 2.9% rise in constant currency. The company reported diluted net earnings per share (GAAP) of $0.69, a decrease from $0.96 in the second quarter of 2024. However, adjusted diluted net earnings per share were $1.15, up from $0.98 in the second quarter of 2024. Looking ahead, CONMED has updated its full-year revenue guidance, now expecting reported revenue to be between $1.356 billion and $1.378 billion, an adjustment from the prior range of $1.350 billion to $1.378 billion. The company noted that currency headwinds are now expected to be immaterial, compared to the previously anticipated 50 to 70 basis points of headwind.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CONMED Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730169915) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CONMED Corporation Reports Q2 2025 Sales Increase of 3.1%; Adjusted EPS Rises to $1.15</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCONMED Corporation Reports Q2 2025 Sales Increase of 3.1%; Adjusted EPS Rises to $1.15\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNMD\">CONMED Corporation</a> Reports <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2025 Sales Increase of 3.1%; Adjusted EPS Rises to $1.15\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CONMED Corporation (NYSE: CNMD) announced its financial results for the second quarter ended June 30, 2025. The company reported sales of $342.3 million, marking a 3.1% increase year-over-year as reported, and a 2.9% increase in constant currency. Domestic revenue rose by 2.8% compared to the previous year, while international revenue saw a 3.4% increase year-over-year as reported, and a 2.9% rise in constant currency. The company reported diluted net earnings per share (GAAP) of $0.69, a decrease from $0.96 in the second quarter of 2024. However, adjusted diluted net earnings per share were $1.15, up from $0.98 in the second quarter of 2024. Looking ahead, CONMED has updated its full-year revenue guidance, now expecting reported revenue to be between $1.356 billion and $1.378 billion, an adjustment from the prior range of $1.350 billion to $1.378 billion. The company noted that currency headwinds are now expected to be immaterial, compared to the previously anticipated 50 to 70 basis points of headwind.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CONMED Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730169915) on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNMD","symbol_name":"CONMED Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDLGmsfQ:1","article_id":"2555840024","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555840024","pubTimestamp":1753906009,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CONMED Corporation  announced its financial results for the second quarter ended June 30, 2025. The company reported sales of $342.3 million, marking a 3.1% increase year-over-year as reported, and a 2.9% increase in constant currency. Domestic revenue rose by 2.8% compared to the previous year, while international revenue saw a 3.4% increase year-over-year as reported, and a 2.9% rise in constant currency. The company reported diluted net earnings per share  of $0.69, a decrease from $0.96 in the second quarter of 2024. However, adjusted diluted net earnings per share were $1.15, up from $0.98 in the second quarter of 2024. Looking ahead, CONMED has updated its full-year revenue guidance, now expecting reported revenue to be between $1.356 billion and $1.378 billion, an adjustment from the prior range of $1.350 billion to $1.378 billion. The company noted that currency headwinds are now expected to be immaterial, compared to the previously anticipated 50 to 70 basis points of headwind","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CNMD":"CONMED Corporation"},"translate_title":"CONMED Corporation报告2025年第二季度销售额增长3.1%；调整后每股收益升至1.15美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNMD":0.9},"content_text":"CONMED Corporation Reports Q2 2025 Sales Increase of 3.1%; Adjusted EPS Rises to $1.15\n    \n\n        CONMED Corporation (NYSE: CNMD) announced its financial results for the second quarter ended June 30, 2025. The company reported sales of $342.3 million, marking a 3.1% increase year-over-year as reported, and a 2.9% increase in constant currency. Domestic revenue rose by 2.8% compared to the previous year, while international revenue saw a 3.4% increase year-over-year as reported, and a 2.9% rise in constant currency. The company reported diluted net earnings per share (GAAP) of $0.69, a decrease from $0.96 in the second quarter of 2024. However, adjusted diluted net earnings per share were $1.15, up from $0.98 in the second quarter of 2024. Looking ahead, CONMED has updated its full-year revenue guidance, now expecting reported revenue to be between $1.356 billion and $1.378 billion, an adjustment from the prior range of $1.350 billion to $1.378 billion. The company noted that currency headwinds are now expected to be immaterial, compared to the previously anticipated 50 to 70 basis points of headwind.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CONMED Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730169915) on July 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}